Duncan Bull

Associate

Duncan joined Kilburn & Strode in September 2018 as an Attorney in the Life Sciences and Chemistry group, having previously worked for another leading firm of patent attorneys.
 
Duncan is a UK and European patent attorney with experience of coordinating large portfolios across multiple jurisdictions. Duncan has been involved with a number of contentious patent matters, including defence of a key patent covering a blockbuster drug against a large, multi-party EPO opposition. He has also been involved in a number of due diligence and freedom-to-operate projects for both large and small clients.
 
Duncan has been closely involved with developing the IP strategy of a small biotech firm, including the drafting and prosecution of a number of second medical use patents, and particularly enjoys helping clients to understand and overcome challenges in the patent system. Duncan’s day-to-day workload includes areas such as antibodies, vaccines, protein-based therapeutics, biomarker diagnostics, formulations and certain medical devices.
 
Duncan graduated with an MSci in Natural Sciences (Biochemistry) from Christ’s College, University of Cambridge before going on to complete a PhD at the MRC London Institute of Medical Sciences. During his PhD he investigated the role of a novel protein kinase in metabolic processes, which involved collaborations with a number of other academics and a pharmaceutical firm.
 

Qualifications

Chartered UK Patent Attorney
European Patent Attorney 
Certificate in Intellectual Property Law – Queen Mary University
PhD in Medical Biochemistry – Imperial College London
MA/MSci in Natural Sciences (Biochemistry) – University of Cambridge

Memberships

Chartered Institute of Patent Attorneys (CIPA) 
The Institute of Professional Representatives before the European Patent Office (EPI) 

  • Biotechnology
  • Medical Devices
  • Biologics
  • Pharmaceuticals
  • Patents

The life sciences and chemistry team regularly writes about trends, developments and legal updates in the IP industry in our News & insights hub.

Read here

Cookies improve the way our website works. By using this website you are agreeing to our use of cookies. For more information see our cookie policy I accept